Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allogeneic Stem Cell-derived Pancreatic Islets
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : iTolerance
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : iTOL-102 is our lead program that is developed Using our proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.
Brand Name : iTOL-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 07, 2023
Lead Product(s) : Allogeneic Stem Cell-derived Pancreatic Islets
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : iTolerance
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Allogenic Pancreatic Islet Cell
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : iTolerance
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Kadimastem will supply its advanced cell product, IsletRx and iTolerance will provide its iTOL-100 immunomodulatory technology for the development of iTOL-102 (allogenic pancreatic islet cell) for the treatment of Type 1 Diabetes.
Brand Name : iTOL-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 18, 2023
Lead Product(s) : Allogenic Pancreatic Islet Cell
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : iTolerance
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Human pluripotent stem cells
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kadimastem Granted a Patent in Israel for the Treatment of ALS
Details : Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.
Brand Name : AstroRx
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : Human pluripotent stem cells
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human astrocytes
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
Details : The primary objective of the trial was to evaluate the safety of AstroRx®, an "off-the-shelf", clinical-grade, astrocyte cell product, developed and manufactured by the Company. The trial met its endpoints.
Brand Name : AstroRx
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 15, 2020
Lead Product(s) : Human astrocytes
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human astrocytes
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Kadimastem's lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.
Brand Name : AstroRx
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 03, 2020
Lead Product(s) : Human astrocytes
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AstroRx
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kadimastem reports positive ALS cell therapy results
Details : A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 02, 2020
Lead Product(s) : AstroRx
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?